

Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness and Value

Thursday, October 20, 2016; 10:00 AM – 4:00 PM

Agenda

Century BC Room, Millenium Student Center University of Missouri-St. Louis 1 University Blvd, St. Louis, MO 63121

Time	Activity	
9:30 am – 10:00 am	Registration	
10:00 am – 10:15 am	 Meeting Convened and Opening Remarks: Steven Pearson, MD, MSc, President, ICER 	
10:15 am – 11:30 am	 Presentation of the Evidence: David Rind, MD, MSc, ICER Greg Guzauskas, University of Washington Rick Chapman, PhD, MS, ICER Q&A 	
11:30 am – 11:45 am	Public Comments and Discussion: Members of the public pre-registered to deliver oral remarks	
11:45 am – 12:15 pm	Manufacturer Comments and Discussion	
12:15 pm – 12:45 pm	Break for Lunch	
12:45 pm – 2:15 pm	Midwest CEPAC Q&A with Clinical Experts Midwest CEPAC Deliberation and Votes: ICER staff and clinical experts will be available for questions from the Council during deliberation	
2:15 pm – 3:45 pm	Policy Roundtable	
3:45 pm – 4:00 pm	Meeting Adjourned	

Meeting Participants

Midwest CEPAC Panel

Name	Organization	Disclosure
Eric Armbrecht, PhD	St Louis University Center for Health Outcomes Research	*
Ryan Barker	Missouri Foundation for Health	*
Aaron Carroll, MD	Indiana University School of Medicine	*
Donald Casey, MD, MPH, MBA	Alvarez & Marsal Healthcare Industry Group; IPO4Health; Jefferson College of Population Health; Rush Medical College	*
Rena Conti, PhD	University of Chicago	*
Susan Feigenbaum, Ph.D.	University of Missouri, St. Louis	*
Jill Johnson, Pharm. D.	University of Arkansas for Medical Sciences	*
Mary Klix, MD	SLUCare Physician Group	*
Janice Meyer, MSN	St. Anthony's Health Care Partners	*
Rajiv Patel, MD	SSM DePaul Hospital	*
Harold Pollack, PHD	University of Chicago	*
Scott Micek, Pharm. D.	St. Louis College of Pharmacy	*
Reem Mustafa, MD	University of Missouri-Kansas City School of Medicine	*
Shumei Yun, MD, PhD	MO Department of Health and Senior Services	*

*No conflicts of interest to disclose, defined as more than \$10,000 in health care company stock or more than \$5,000 in honoraria or consultancies during the previous year from relevant health care manufacturers or insurers.

Institute for Clinical and Economic Review (ICER) Staff and Consultants

- Anirban Basu, Professor and Director of Pharmaceutical Outcomes Research and Policy Program, University of Washington
- **Greg Guzauskas,** Senior Research Scientist, University of Washington
- Rick Chapman, PhD, MS, Director of Health Economics, ICER
- Sonya Khan, MPH, Program Director, ICER
- David Rind, MD, Chief Medical Officer, ICER
- Steve Pearson, MD, MSc, President, ICER
- Shanshan Liu, Research Associate, ICER
- Maggie Webb, Program and Event Coordinator, ICER